2.15
price down icon5.70%   -0.13
after-market Dopo l'orario di chiusura: 2.15
loading
Precedente Chiudi:
$2.28
Aprire:
$2.26
Volume 24 ore:
1.28M
Relative Volume:
0.74
Capitalizzazione di mercato:
$128.79M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-2.8667
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
-3.15%
1M Prestazione:
-20.07%
6M Prestazione:
-56.12%
1 anno Prestazione:
-42.36%
Intervallo 1D:
Value
$2.10
$2.26
Intervallo di 1 settimana:
Value
$2.10
$2.30
Portata 52W:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Nome
Aldeyra Therapeutics Inc
Name
Telefono
781-761-4904
Name
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Dipendente
8
Name
Cinguettio
@aldeyraaldx
Name
Prossima data di guadagno
2024-11-18
Name
Ultimi documenti SEC
Name
ALDX's Discussions on Twitter

Confronta ALDX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
2.15 132.97M 0 -44.80M -30.67M -0.75
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-03 Aggiornamento Oppenheimer Perform → Outperform
2024-04-02 Ripresa H.C. Wainwright Buy
2022-04-27 Ripresa H.C. Wainwright Buy
2021-02-08 Iniziato H.C. Wainwright Buy
2020-12-16 Iniziato Berenberg Buy
2020-10-30 Iniziato Jefferies Buy
2020-10-16 Iniziato BTIG Research Buy
2020-09-22 Iniziato Alliance Global Partners Buy
2020-05-12 Iniziato Oppenheimer Outperform
2018-12-04 Iniziato Citigroup Buy
2018-09-26 Reiterato Cantor Fitzgerald Overweight
2018-09-13 Iniziato Janney Buy
2018-01-26 Iniziato Seaport Global Securities Buy
2016-09-26 Iniziato H.C. Wainwright Buy
2016-07-01 Iniziato Stifel Buy
2015-07-01 Iniziato Canaccord Genuity Buy
2015-03-25 Iniziato Chardan Capital Markets Buy
2015-03-20 Reiterato H.C. Wainwright Buy
2014-11-18 Iniziato H.C. Wainwright Buy
2014-06-19 Iniziato Aegis Capital Buy
Mostra tutto

Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie

pulisher
May 29, 2025

Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire

May 29, 2025
pulisher
May 26, 2025

Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 26, 2025
pulisher
May 25, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World

May 25, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 24, 2025
pulisher
May 23, 2025

Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World

May 23, 2025
pulisher
May 22, 2025

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World

May 22, 2025
pulisher
May 22, 2025

Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World

May 22, 2025
pulisher
May 21, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World

May 21, 2025
pulisher
May 20, 2025

Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 20, 2025
pulisher
May 20, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

(ALDX) Trading Report - news.stocktradersdaily.com

May 18, 2025
pulisher
May 18, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent

May 18, 2025
pulisher
May 18, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 14, 2025

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune

May 14, 2025
pulisher
May 14, 2025

Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 13, 2025
pulisher
May 12, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire

May 12, 2025
pulisher
May 11, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 11, 2025
pulisher
May 08, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune

May 07, 2025
pulisher
May 07, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView

May 07, 2025
pulisher
May 07, 2025

Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st

May 07, 2025
pulisher
May 07, 2025

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Aldeyra makes third run at FDA approval for dry eye drug - The Pharma Letter

May 07, 2025
pulisher
May 06, 2025

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data - insights.citeline.com

May 06, 2025
pulisher
May 06, 2025

Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech

May 06, 2025
pulisher
May 06, 2025

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 06, 2025
pulisher
May 06, 2025

Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data - Endpoints News

May 06, 2025
pulisher
May 06, 2025

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan

May 05, 2025
pulisher
May 05, 2025

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire

May 05, 2025
pulisher
May 05, 2025

ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com

May 05, 2025
pulisher
May 05, 2025

Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 05, 2025
pulisher
May 03, 2025

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire

May 03, 2025
pulisher
May 03, 2025

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.

May 03, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 02, 2025
pulisher
May 01, 2025

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation - TradingView

May 01, 2025
pulisher
May 01, 2025

Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com

May 01, 2025

Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):